A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam or Brivaracetam
Latest Information Update: 23 Jul 2024
At a glance
- Drugs ADX 71149 (Primary) ; Brivaracetam; Levetiracetam
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 22 Jul 2024 According to an Addex Therapeutics media release, the company announced that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.
- 29 Apr 2024 Results presented in an Addex Therapeutics Media Release.
- 29 Apr 2024 Primary endpoint (Time to Baseline Monthly Seizure Count up to the end of the 12-week Double-blind Treatment Period) has not been met, according to an Addex Therapeutics media release.